• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Health

Omicron causes less severe illness even in the unvaccinated, South Africa study says

By
Antony Sguazzin
Antony Sguazzin
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Antony Sguazzin
Antony Sguazzin
and
Bloomberg
Bloomberg
Down Arrow Button Icon
January 14, 2022, 4:26 AM ET

The Omicron coronavirus variant causes less severe disease than the Delta strain even in those who are unvaccinated or who haven’t had a prior COVID-19 infection, a study from South Africa’s Western Cape province showed. 

The research in the region where Cape Town is the capital compared 11,609 patients from the first three waves of infection, the most recent of which was caused by the delta variant, and 5,144 patients from the latest Omicron-driven wave.

The findings add to growing evidence that while more infectious, Omicron may be less virulent than predecessors. Data from South Africa, the first country to have a major outbreak caused by the strain, has so far shown lower hospitalization and death rates.

Still, with over a quarter of the population vaccinated and a prior infection rate of 70% to 80%, there has been concern that that may be masking the danger presented by the variant.

“Ours is the first study from a setting of high prior seroprevalence to demonstrate less severe disease in wave four after adjusting for both vaccination and prior diagnosed infection,” the researchers said in the study. “Even after this protection was considered there was a likely reduction of the most severe outcomes in wave four,” indicating possible reduction in virulence of Omicron, the said.

Less Deadly

The study, which was released this week and is yet to be peer reviewed, focused on public hospitals in the province. It was led by Mary Ann-Davies, an associate professor at the University of Cape Town. She is also affiliated to the Western Cape government’s Health Impact Assessment Inspectorate.

It found that 8% of people were hospitalized or died within 14 days of being diagnosed with COVID-19 in the Omicron-driven wave compared with 16.5% over the three earlier waves. 

“After adjusting for age, sex, comorbidities and subdistrict there was a substantially reduced hazard of death in wave four compared to wave three,” the researchers said. “The extent of reduction was attenuated when additionally considering prior diagnosed infections and vaccination.”

Still, even when prior infections were factored in there was a 25% lower risk of dying in wave four than wave three, they said. However, after adjustments for immunity from vaccinations or earlier infections were made, Omicron presented a similar risk to the version of the virus first identified in Wuhan, China.

The researchers warned that given the infectious nature of Omicron, public health systems still need to plan carefully for outbreaks because of the potential surge of patients. 

“We found substantially reduced disease severity among diagnosed COVID-19 cases in the Omicron-driven fourth wave compared to previous waves,” the researchers said. Even accounting for vaccinations and prior infections, the data suggests “intrinsically reduced virulence of Omicron.”

Never miss a story: Follow your favorite topics and authors to get a personalized email with the journalism that matters most to you.

About the Authors
By Antony Sguazzin
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.